47 results
8-K
EX-99.1
LUMO
Lumos Pharma Inc
30 Nov 22
Other Events
6:27pm
applying innovative genetic technologies to pediatric endocrinology. Dr. Dauber has served as the program director and director of translational
8-K/A
LUMO
Lumos Pharma Inc
1 Jun 20
Other Events
12:00am
States, there is a process to authorize generic versions of innovative drugs in the European Union. Generic competitors can, where data exclusivity has
8-K
EX-99.1
ban pp9z7ypqp0mf8f
18 Mar 20
NewLink Genetics Stockholders Approve Merger with Lumos Pharma
4:37pm
DEFR14A
ph3amn37
13 Feb 20
Revised proxy
4:37pm
DEFM14A
zo33xdx
10 Feb 20
Proxy related to merger
8:30am
PRER14A
bqs 4r9z3lu2ww0
9 Jan 20
Preliminary revised proxy
8:02am
PREM14A
m24x1g2o 8diqff
20 Nov 19
Preliminary proxy related to merger
6:38am
8-K
wrdjgt jpq
1 May 18
NewLink Genetics Appoints Matthew L. Sherman, M.D. to Board of Directors
9:11am
8-K
EX-99.1
9agnq jlj5e0k21jx
1 May 18
NewLink Genetics Appoints Matthew L. Sherman, M.D. to Board of Directors
9:11am